Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial
PhotoTeclistamab Shows Higher Response Rates Than Standard Therapy in High-Risk Smoldering Myeloma | Late-Night Snacking Linked to 20-30% Higher Risk of Liver Disease